Why the study?
Oxaliplatin frequently induces peripheral neuropathy, particularly cold allodynia, but the underlying mechanisms remain elusive.
Does liposomal oxaliplatin reduce cold allodynia and improve antitumor efficacy compared to free oxaliplatin in mice?
Does liposomal oxaliplatin reduce cold allodynia and improve antitumor efficacy compared to free oxaliplatin in mice?
Nanoformulated oxaliplatin reduces chemotherapy-induced peripheral neuropathy (cold allodynia) by decreasing platinum accumulation in dermal fibroblasts while enhancing antitumor efficacy in mice.
Answers are grounded in this paper and cite their sources.
Liposomal OXA may reduce cold allodynia via indirect mechanisms; leaves open clinical translation in patients.
Oxaliplatin (OXA) is a third-generation platinum-based chemotherapeutic drug for cancer therapy. However, OXA frequently induces peripheral neuropathy, especially cold allodynia, while the underlying mechanisms remain elusive. Herein, we notice that liposomal OXA (Lip-OXA) alleviates cold allodynia in mice compared with free OXA, despite comparable platinum accumulation levels in neural tissues in these two groups, suggesting indirect pathways stimulate peripheral nerves during the OXA therapy. Further investigation indicates that platinum accumulation in dermal extracellular matrix-associated fibroblasts activates the nuclear factor κB (NF-κB) pathway, followed by activation of the chemokine (C-C motif) ligand 2 (CCL2)/C-C motif chemokine receptor 2 (CCR2)/transforming receptor potential cation channel subfamily M member 8 (TRPM8) axis to induce cold allodynia. Nanoformulated OXA treatment reduces cold allodynia due to lower platinum accumulation in the dermis (than that of free OXA). Notably, Lip-OXA shows a superior antitumor efficacy over free OXA in an in situ colorectal cancer model. These findings expand the mechanisms underlying OXA-induced cold allodynia and suggest that nanoformulated OXA can effectively alleviate chemotherapy-induced peripheral neuropathy, while enhancing therapeutic efficacy.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: